Immunotherapy combo shows promise in rectal cancer after standard treatment
NCT ID NCT05009069
First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This study tests whether adding two immunotherapy drugs (atezolizumab and tiragolumab) after standard chemoradiation can help eliminate tumors in people with locally advanced rectal cancer. About 58 participants will receive either the drug combination or atezolizumab alone before surgery. The main goal is to see if the cancer completely disappears by the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beijing Cancer Hospital
Beijing, 100142, China
-
First Hospital of China Medical University
Shenyang, 110001, China
-
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, 310009, China
-
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, 510655, China
-
Zhongshan Hospital Fudan University
Shanghai, 200032, China
Conditions
Explore the condition pages connected to this study.